India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GSK Pharma share price fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight ...

GSK’s entry into Oncology with the launch of specialised therapies Jemperli (Dostarlimab) and Zejula (Niraparib) was ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

ICICI Securities recommended hold rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2500 in its research report dated 09, 2025.

GSK is sticking to its plan to gradually monetize its stake in Haleon, the consumer health business the British pharma giant spun off in 2022. GSK has collected about 978 million pounds ($1.24 billion ...

Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK ...

GSK shares rose to the top of the FTSE 100 leader board after the drugmaker raised its 2025 guidance on the back of a strong third-quarter performance. The earnings were the last to be presented by ...

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK plc has announced provisional dividend dates for the year 2026, outlining key ...